Daniel Serin

2.6k citations

45 papers · 1.6k indexed · h-index 17

Impact in

Cancer Research top 2%
- Breast Cancer Treatment Studies
Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis

Papers in ⓘ

Cancer Research 18
- Breast Cancer Treatment Studies 18
Oncology 32
- Cancer Treatment and Pharmacology 17
- HER2/EGFR in Cancer Research 11
- Global Cancer Incidence and Screening 4
- Lymphatic System and Diseases 3
- Peptidase Inhibition and Analysis 3

Co-authors: Pierre Kerbrat (8 shared papers)Mario Campone (7 shared papers)M. Spielmann (5 shared papers)T. Delozier (3 shared papers)P. Fumoleau (4 shared papers)Henri Roché (6 shared papers)Alain Monnier (4 shared papers)Anne‐Laure Martin (3 shared papers)
Journals: Journal of Clinical Oncology (6 papers)International Journal of Radiation Oncology*Biology*Physics (3 papers)The Oncologist (2 papers)BMC Health Services Research (2 papers)JAMA (1 paper)
Partner nations: France United States Luxembourg

In The Last Decade

Daniel Serin

38 papers receiving 1.5k citations

Peers

Countries citing papers authored by Daniel Serin

Since Specialization

Citations

This map shows the geographic impact of Daniel Serin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Serin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Serin more than expected).

Fields of papers citing papers by Daniel Serin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Serin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Serin. The network helps show where Daniel Serin may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel Serin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel Serin Line = papers co-authored together Daniel Serin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial Journal of Clinical Oncology ·Henri Roché, P. Fumoleau, M. Spielmann, Jean-Luc Canon, T. Delozier, Daniel Serin, Michel Symann, Pierre Kerbrat, P Soulié, Françoise Eichler, Patrice Viens, Alain Monnier, A. Vindevoghel, Mario Campone, Marie-Josèphe Goudier, Jacques Bonneterre, Jean-Marc Ferrero, Anne‐Laure Martin, Jean Genève, Bernard Asselain	2006	401
2	Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial Journal of Clinical Oncology ·M. Spielmann, Henri Roché, T. Delozier, Jean-Luc Canon, Gilles Romieu, Hugues Bourgeois, Jean-Marc Extra, Daniel Serin, Pierre Kerbrat, Jean‐Pascal Machiels, Alain Lortholary, Hubert Orfeuvre, Mario Campone, Anne‐Claire Hardy‐Bessard, Bruno Coudert, Marie Maerevoet, G. Piot, Andrew Kramar, Anne-Laure Martin, Frédérique Penault–Llorca	2009	220
3	6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial The Lancet Oncology ·X. Pivot, Gilles Romieu, Marc Debled, Jean‐Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, P. Fumoleau, Daniel Serin, Jean-Philippe Jacquin, Christelle Jouannaud, María Rios, Sophie Abadie‐Lacourtoisie, N. Tubiana-Mathieu, Laurent Cany, Stéphanie Catala, David Khayat, Iris Pauporté, Andrew Kramar	2013	211
4	Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial Journal of Clinical Oncology ·Bruno Coudert, Rémy Largillier, Laurent Arnould, P. Chollet, Mario Campone, David Coeffic, Frank Priou, Joseph Gligorov, Xavier Pérez Martín, V. Trillet-Lenoir, B. Weber, Jean Pierre Bleuse, B. Vasseur, Daniel Serin, Moïse Namer	2007	102
5	Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study The Oncologist ·Jean-Marc Extra, Eric C. Antoine, Anne Vincent‐Salomon, T. Delozier, Pierre Kerbrat, Anne Béthune-Volters, Jean‐Paul Guastalla, M. Spielmann, L. Mauriac, Jean-Louis Misset, Daniel Serin, Mario Campone, Christophe Hébert, C Remblier, Loïc Bergougnoux, Frank Campana, Moïse Namer	2010	92
6	Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial Journal of Clinical Oncology ·P. Fumoleau, Pierre Kerbrat, P. Romestaing, P. Fargeot, Alain Brémond, Moïse Namer, S Schraub, Marie-Jo Goudier, J. Mihura, Alain Monnier, P. Clavère, Daniel Serin, Philippe Seffert, C Pourny, T. Facchini, Jean-Philippe Jacquin, Jean-François Sztermer, Jean Datchary, René Ramos, Élisabeth Luporsi	2003	80
7	Phase III Trial of Concurrent or Sequential Adjuvant Chemoradiotherapy After Conservative Surgery for Early-Stage Breast Cancer: Final Results of the ARCOSEIN Trial Journal of Clinical Oncology ·Alain Tolédano, D. Azria, P. Garaud, Alain Fourquet, Daniel Serin, Jean-François Bosset, J. Miny-Buffet, A. Favre, O. Le Floch, G. Calais	2007	67
8	Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: Long-term results of the ARCOSEIN multicenter randomized study International Journal of Radiation OncologyBiologyPhysics ·Alain Tolédano, P. Garaud, Daniel Serin, Alain Fourquet, Jean-François Bosset, N. Breteau, G. Body, D. Azria, O. Le Floch, G. Calais	2006	64
9	A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: Final results International Journal of Radiation OncologyBiologyPhysics ·Jacques Rouëssé, Brigitte De La Lande, F. Bertheault-Cvitkovic, Daniel Serin, Y Graïc, M. Combe, Bernard Leduc, Virginie Lucas, Liliane Demange, Tan Dat Nguyen, D. Castéra, C. Krzisch, R. Villet, Emmanuelle Mouret‐Fourme, Jean-Rémy Garbay, Catherine Noguès	2006	53
10	Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial The Oncologist ·Bruno Coudert, Bernard Asselain, Mario Campone, M. Spielmann, Jean‐Pascal Machiels, Frédérique Penault‐Llorca, Daniel Serin, Christelle Lévy, Gilles Romieu, Jean-Luc Canon, Hubert Orfeuvre, G. Piot, Thierry Petit, Guy Jérusalem, B. Audhuy, Corinne Veyret, M. Beauduin, Jean‐Christophe Eymard, Anne‐Laure Martin, Henri Roché, (unknown)	2012	27
11	Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives International Journal of Cardiology ·Jennifer Cautela, Nathalie Lalevée, Chloé Ammar, Stéphane Éderhy, Michaël Peyrol, P. Debourdeau, Daniel Serin, Yvan Le Dolley, Nicolas Michel, Morgane Orabona, Jérémie Barraud, Marc Laine, Laurent Bonello, Franck Paganelli, Fabrice Barlési, Franck Thuny	2016	26
12	Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer Anti-Cancer Drugs ·Thierry Petit, Abdellatif Benider, Alejandro Yovine, Philippe Bougnoux, Dominique Spaëth, F. Maindrault-Gœbel, Daniel Serin, J Tigaud, Jean Christophe Eymard, H. Simon, B. Bertaux, S. Brienza, Esteban Cvitkovic	2006	23
13	Impact of organised programs on colorectal cancer screening BMC Cancer ·François Eisinger, L. Cals, Anne Calazel-Benque, Jean‐Yves Blay, Yvan Coscas, Sylvie Dolbeault, Moïse Namer, Xavier Pivot, Olivier Rixe, Daniel Serin, Claire Roussel, Jean‐François Morère	2008	19
14	Cancer screening in France: subjects’ and physicians’ attitudes Cancer Causes & Control ·François Eisinger, Jean‐Yves Blay, Jean‐François Morère, Olivier Rixe, Anne Calazel-Benque, L. Cals, Yvan Coscas, Sylvie Dolbeault, Moïse Namer, Daniel Serin, Claire Roussel, Xavier Pivot	2007	19
15	Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial Breast Cancer Research ·Jocelyne Jacquemier, Jean‐Marie Boher, Henri Roché, Benjamin Esterni, Daniel Serin, Pierre Kerbrat, Fabrice André, Pascal Finetti, Emmanuelle Charafe‐Jauffret, Anne‐Laure Martin, Mario Campone, Patrice Viens, Daniel Birnbaum, Frédérique Penault‐Llorca, François Bertucci	2011	18
16	[For a coordination of the supportive care for people affected by severe illnesses: proposition of organization in the public and private health care centres]. PubMed ·I. Krakowski, F. Boureau, R. Bugat, Laurent Chassignol, Philippe Colombat, Laure Copel, Daniel D’Hérouville, Marylène Filbet, Bernard Laurent, Nadine Memran, J. Meynadier, G. Parmentier, Philippe Poulain, P. Saltel, Daniel Serin, Jean-Philippe Wagner	2004	18
17	Does Concurrent Radiochemotherapy Affect Cosmetic Results in the Adjuvant Setting After Breast-Conserving Surgery? Results of the ARCOSEIN Multicenter, Phase III Study: Patients’ and Doctors’ Views International Journal of Radiation OncologyBiologyPhysics ·Alain Tolédano, Marc A. Bollet, Alain Fourquet, D. Azria, Joseph Gligorov, P. Garaud, Daniel Serin, Jean-François Bosset, J. Miny-Buffet, A. Favre, Olivier LeFoch, G. Calais	2007	17
18	Development and feasibility of a set of quality indicators relative to the timeliness and organisation of care for new breast cancer patients undergoing surgery BMC Health Services Research ·Marie Ferrua, Mélanie Couralet, Gérard Nitenberg, Sandrine Morin, Daniel Serin, Étienne Minvielle	2012	12
19	Assessment of Care by Breast Cancer Patients Participating or Not Participating in a Randomized Controlled Trial: A Report With the Patients' Committee for Clinical Trials of the Ligue Nationale Contre le Cancer Journal of Clinical Oncology ·Claire Julian‐Reynier, Jean Genève, Florence Dalenc, Dominique Genre, Alain Monnier, Pierre Kerbrat, Rémy Largillier, Daniel Serin, María Rios, Henri Roché, Marta Jiménez, Carole Tarpin, D Maraninchi	2007	11
20	[Parcours de femmes. Opinion survey carried out among women treated for gynecologic and breast cancers and their medical care teams]. PubMed ·Daniel Serin, H Pujol, S Schraub, H Chevalier	1998	11

About Daniel Serin

Daniel Serin is a scholar working on Cancer Research, Oncology, Public Health, Environmental and Occupational Health, Otorhinolaryngology and Pathology and Forensic Medicine, having authored 45 papers that have together received 1.6k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (18 papers), Cancer Treatment and Pharmacology (17 papers), HER2/EGFR in Cancer Research (11 papers), Global Cancer Incidence and Screening (4 papers), Breast Lesions and Carcinomas (4 papers), Lymphatic System and Diseases (3 papers), Health, Medicine and Society (3 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Cancer Research (808 citations), Oncology (1.3k citations), Radiology, Nuclear Medicine and Imaging (302 citations), Pathology and Forensic Medicine (164 citations) and Dermatology (67 citations). Daniel Serin has collaborated with scholars based in France, United States and Luxembourg. Frequent co-authors include Pierre Kerbrat, Mario Campone, M. Spielmann, T. Delozier, P. Fumoleau, Henri Roché, Alain Monnier, Anne‐Laure Martin, Gilles Romieu and Alain Lortholary. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, The Oncologist, BMC Health Services Research and JAMA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact